ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Opioid-Induced Constipation Market Research Report 2024
Published Date: February 2024
|
Report Code: QYRE-Auto-716
Home | Market Reports | Health| Pharmacy| Drugs & Medications
Global Opioid Induced Constipation Market Size Manufacturers Supply Chain Sales Channel and Clients 2021 2027
BUY CHAPTERS

Global Opioid-Induced Constipation Market Research Report 2024

Code: QYRE-Auto-716
Report
February 2024
Pages:88
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Sanofi
Mallinckrodt plc
ch Health)
Astrazeneca plc
Progenics Pharmaceuticals
Purdue Pharm
Nektar Therapeutics
Daiichi Sankyo
Prestige
GSK
Shionogi
Salix
Takeda Pharmaceutical
Takeda Pharmaceuticals
Bayer
Salix (Bausch Health)

Opioid-Induced Constipation Market Size

The global Opioid-Induced Constipation market was valued at US$ 2531 million in 2023 and is anticipated to reach US$ 3480.4 million by 2030, witnessing a CAGR of 4.6% during the forecast period 2024-2030.

Opioid-Induced Constipation Market

Opioid-Induced Constipation Market

Although opioids are very effective for treating and managing pain, their use frequently results in opioid-induced constipation (OIC). Treatment options for OIC may be as simple as changing diet or as complicated as requiring several medicines and laxatives.
Global Opioid-Induced Constipation key players include Sanofi, Bayer, Purdue Pharm, etc. Global top three manufacturers hold a share over 45%.
North America is the largest market, with a share about 55%, followed by Europe, and Asia-Pacific, both have a share about 35 percent.
In terms of product, Lubiprostone is the largest segment, with a share about 5%. And in terms of application, the largest application is Pharmacy, followed by Hospital, etc.
This report aims to provide a comprehensive presentation of the global market for Opioid-Induced Constipation, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Opioid-Induced Constipation.

Report Scope

The Opioid-Induced Constipation market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Opioid-Induced Constipation market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Opioid-Induced Constipation manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Opioid-Induced Constipation Market Report

Report Metric Details
Report Name Opioid-Induced Constipation Market
Accounted market size in 2023 US$ 2531 million
Forecasted market size in 2030 US$ 3480.4 million
CAGR 4.6%
Base Year 2023
Forecasted years 2024 - 2030
Segment by Type
  • Methylnaltrexone Bromide
  • Lubiprostone
  • Naloxegol
  • Others
Segment by Application
  • Hospital
  • Pharmacy
  • Other
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Takeda Pharmaceuticals, Bayer, Sanofi, Mallinckrodt, Salix (Bausch Health), AstraZeneca, Progenics Pharmaceuticals, Purdue Pharm, Nektar Therapeutics, Daiichi Sankyo, Prestige, GSK, Shionogi
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Opioid-Induced Constipation manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Opioid-Induced Constipation in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report.

FAQ for this report

How fast is Opioid-Induced Constipation Market growing?

Ans: The Opioid-Induced Constipation Market witnessing a CAGR of 4.6% during the forecast period 2024-2030.

What is the Opioid-Induced Constipation Market size in 2030?

Ans: The Opioid-Induced Constipation Market size in 2030 will be US$ 3480.4 million.

What is the market share of major companies in Opioid-Induced Constipation Market?

Ans: Global top three manufacturers hold a share over 45%.

What is the Opioid-Induced Constipation Market share by type?

Ans: In terms of product, Lubiprostone is the largest segment, with a share about 5%.

Who are the main players in the Opioid-Induced Constipation Market report?

Ans: The main players in the Opioid-Induced Constipation Market are Takeda Pharmaceuticals, Bayer, Sanofi, Mallinckrodt, Salix (Bausch Health), AstraZeneca, Progenics Pharmaceuticals, Purdue Pharm, Nektar Therapeutics, Daiichi Sankyo, Prestige, GSK, Shionogi

What are the Application segmentation covered in the Opioid-Induced Constipation Market report?

Ans: The Applications covered in the Opioid-Induced Constipation Market report are Hospital, Pharmacy, Other

What are the Type segmentation covered in the Opioid-Induced Constipation Market report?

Ans: The Types covered in the Opioid-Induced Constipation Market report are Methylnaltrexone Bromide, Lubiprostone, Naloxegol, Others

1 Opioid-Induced Constipation Market Overview
1.1 Product Overview and Scope of Opioid-Induced Constipation
1.2 Opioid-Induced Constipation Segment by Type
1.2.1 Global Opioid-Induced Constipation Market Value Comparison by Type (2024-2030)
1.2.2 Methylnaltrexone Bromide
1.2.3 Lubiprostone
1.2.4 Naloxegol
1.2.5 Others
1.3 Opioid-Induced Constipation Segment by Application
1.3.1 Global Opioid-Induced Constipation Market Value by Application: (2024-2030)
1.3.2 Hospital
1.3.3 Pharmacy
1.3.4 Other
1.4 Global Opioid-Induced Constipation Market Size Estimates and Forecasts
1.4.1 Global Opioid-Induced Constipation Revenue 2019-2030
1.4.2 Global Opioid-Induced Constipation Sales 2019-2030
1.4.3 Global Opioid-Induced Constipation Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Opioid-Induced Constipation Market Competition by Manufacturers
2.1 Global Opioid-Induced Constipation Sales Market Share by Manufacturers (2019-2024)
2.2 Global Opioid-Induced Constipation Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Opioid-Induced Constipation Average Price by Manufacturers (2019-2024)
2.4 Global Opioid-Induced Constipation Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Opioid-Induced Constipation, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Opioid-Induced Constipation, Product Type & Application
2.7 Opioid-Induced Constipation Market Competitive Situation and Trends
2.7.1 Opioid-Induced Constipation Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Opioid-Induced Constipation Players Market Share by Revenue
2.7.3 Global Opioid-Induced Constipation Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Opioid-Induced Constipation Retrospective Market Scenario by Region
3.1 Global Opioid-Induced Constipation Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Opioid-Induced Constipation Global Opioid-Induced Constipation Sales by Region: 2019-2030
3.2.1 Global Opioid-Induced Constipation Sales by Region: 2019-2024
3.2.2 Global Opioid-Induced Constipation Sales by Region: 2025-2030
3.3 Global Opioid-Induced Constipation Global Opioid-Induced Constipation Revenue by Region: 2019-2030
3.3.1 Global Opioid-Induced Constipation Revenue by Region: 2019-2024
3.3.2 Global Opioid-Induced Constipation Revenue by Region: 2025-2030
3.4 North America Opioid-Induced Constipation Market Facts & Figures by Country
3.4.1 North America Opioid-Induced Constipation Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Opioid-Induced Constipation Sales by Country (2019-2030)
3.4.3 North America Opioid-Induced Constipation Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Opioid-Induced Constipation Market Facts & Figures by Country
3.5.1 Europe Opioid-Induced Constipation Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Opioid-Induced Constipation Sales by Country (2019-2030)
3.5.3 Europe Opioid-Induced Constipation Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Opioid-Induced Constipation Market Facts & Figures by Country
3.6.1 Asia Pacific Opioid-Induced Constipation Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Opioid-Induced Constipation Sales by Country (2019-2030)
3.6.3 Asia Pacific Opioid-Induced Constipation Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Opioid-Induced Constipation Market Facts & Figures by Country
3.7.1 Latin America Opioid-Induced Constipation Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Opioid-Induced Constipation Sales by Country (2019-2030)
3.7.3 Latin America Opioid-Induced Constipation Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Opioid-Induced Constipation Market Facts & Figures by Country
3.8.1 Middle East and Africa Opioid-Induced Constipation Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Opioid-Induced Constipation Sales by Country (2019-2030)
3.8.3 Middle East and Africa Opioid-Induced Constipation Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Opioid-Induced Constipation Sales by Type (2019-2030)
4.1.1 Global Opioid-Induced Constipation Sales by Type (2019-2024)
4.1.2 Global Opioid-Induced Constipation Sales by Type (2025-2030)
4.1.3 Global Opioid-Induced Constipation Sales Market Share by Type (2019-2030)
4.2 Global Opioid-Induced Constipation Revenue by Type (2019-2030)
4.2.1 Global Opioid-Induced Constipation Revenue by Type (2019-2024)
4.2.2 Global Opioid-Induced Constipation Revenue by Type (2025-2030)
4.2.3 Global Opioid-Induced Constipation Revenue Market Share by Type (2019-2030)
4.3 Global Opioid-Induced Constipation Price by Type (2019-2030)
5 Segment by Application
5.1 Global Opioid-Induced Constipation Sales by Application (2019-2030)
5.1.1 Global Opioid-Induced Constipation Sales by Application (2019-2024)
5.1.2 Global Opioid-Induced Constipation Sales by Application (2025-2030)
5.1.3 Global Opioid-Induced Constipation Sales Market Share by Application (2019-2030)
5.2 Global Opioid-Induced Constipation Revenue by Application (2019-2030)
5.2.1 Global Opioid-Induced Constipation Revenue by Application (2019-2024)
5.2.2 Global Opioid-Induced Constipation Revenue by Application (2025-2030)
5.2.3 Global Opioid-Induced Constipation Revenue Market Share by Application (2019-2030)
5.3 Global Opioid-Induced Constipation Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Takeda Pharmaceuticals
6.1.1 Takeda Pharmaceuticals Corporation Information
6.1.2 Takeda Pharmaceuticals Description and Business Overview
6.1.3 Takeda Pharmaceuticals Opioid-Induced Constipation Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Takeda Pharmaceuticals Opioid-Induced Constipation Product Portfolio
6.1.5 Takeda Pharmaceuticals Recent Developments/Updates
6.2 Bayer
6.2.1 Bayer Corporation Information
6.2.2 Bayer Description and Business Overview
6.2.3 Bayer Opioid-Induced Constipation Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Bayer Opioid-Induced Constipation Product Portfolio
6.2.5 Bayer Recent Developments/Updates
6.3 Sanofi
6.3.1 Sanofi Corporation Information
6.3.2 Sanofi Description and Business Overview
6.3.3 Sanofi Opioid-Induced Constipation Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Sanofi Opioid-Induced Constipation Product Portfolio
6.3.5 Sanofi Recent Developments/Updates
6.4 Mallinckrodt
6.4.1 Mallinckrodt Corporation Information
6.4.2 Mallinckrodt Description and Business Overview
6.4.3 Mallinckrodt Opioid-Induced Constipation Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Mallinckrodt Opioid-Induced Constipation Product Portfolio
6.4.5 Mallinckrodt Recent Developments/Updates
6.5 Salix (Bausch Health)
6.5.1 Salix (Bausch Health) Corporation Information
6.5.2 Salix (Bausch Health) Description and Business Overview
6.5.3 Salix (Bausch Health) Opioid-Induced Constipation Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Salix (Bausch Health) Opioid-Induced Constipation Product Portfolio
6.5.5 Salix (Bausch Health) Recent Developments/Updates
6.6 AstraZeneca
6.6.1 AstraZeneca Corporation Information
6.6.2 AstraZeneca Description and Business Overview
6.6.3 AstraZeneca Opioid-Induced Constipation Sales, Revenue and Gross Margin (2019-2024)
6.6.4 AstraZeneca Opioid-Induced Constipation Product Portfolio
6.6.5 AstraZeneca Recent Developments/Updates
6.7 Progenics Pharmaceuticals
6.6.1 Progenics Pharmaceuticals Corporation Information
6.6.2 Progenics Pharmaceuticals Description and Business Overview
6.6.3 Progenics Pharmaceuticals Opioid-Induced Constipation Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Progenics Pharmaceuticals Opioid-Induced Constipation Product Portfolio
6.7.5 Progenics Pharmaceuticals Recent Developments/Updates
6.8 Purdue Pharm
6.8.1 Purdue Pharm Corporation Information
6.8.2 Purdue Pharm Description and Business Overview
6.8.3 Purdue Pharm Opioid-Induced Constipation Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Purdue Pharm Opioid-Induced Constipation Product Portfolio
6.8.5 Purdue Pharm Recent Developments/Updates
6.9 Nektar Therapeutics
6.9.1 Nektar Therapeutics Corporation Information
6.9.2 Nektar Therapeutics Description and Business Overview
6.9.3 Nektar Therapeutics Opioid-Induced Constipation Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Nektar Therapeutics Opioid-Induced Constipation Product Portfolio
6.9.5 Nektar Therapeutics Recent Developments/Updates
6.10 Daiichi Sankyo
6.10.1 Daiichi Sankyo Corporation Information
6.10.2 Daiichi Sankyo Description and Business Overview
6.10.3 Daiichi Sankyo Opioid-Induced Constipation Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Daiichi Sankyo Opioid-Induced Constipation Product Portfolio
6.10.5 Daiichi Sankyo Recent Developments/Updates
6.11 Prestige
6.11.1 Prestige Corporation Information
6.11.2 Prestige Opioid-Induced Constipation Description and Business Overview
6.11.3 Prestige Opioid-Induced Constipation Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Prestige Opioid-Induced Constipation Product Portfolio
6.11.5 Prestige Recent Developments/Updates
6.12 GSK
6.12.1 GSK Corporation Information
6.12.2 GSK Opioid-Induced Constipation Description and Business Overview
6.12.3 GSK Opioid-Induced Constipation Sales, Revenue and Gross Margin (2019-2024)
6.12.4 GSK Opioid-Induced Constipation Product Portfolio
6.12.5 GSK Recent Developments/Updates
6.13 Shionogi
6.13.1 Shionogi Corporation Information
6.13.2 Shionogi Opioid-Induced Constipation Description and Business Overview
6.13.3 Shionogi Opioid-Induced Constipation Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Shionogi Opioid-Induced Constipation Product Portfolio
6.13.5 Shionogi Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Opioid-Induced Constipation Industry Chain Analysis
7.2 Opioid-Induced Constipation Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Opioid-Induced Constipation Production Mode & Process
7.4 Opioid-Induced Constipation Sales and Marketing
7.4.1 Opioid-Induced Constipation Sales Channels
7.4.2 Opioid-Induced Constipation Distributors
7.5 Opioid-Induced Constipation Customers
8 Opioid-Induced Constipation Market Dynamics
8.1 Opioid-Induced Constipation Industry Trends
8.2 Opioid-Induced Constipation Market Drivers
8.3 Opioid-Induced Constipation Market Challenges
8.4 Opioid-Induced Constipation Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Sanofi
Mallinckrodt plc
ch Health)
Astrazeneca plc
Progenics Pharmaceuticals
Purdue Pharm
Nektar Therapeutics
Daiichi Sankyo
Prestige
GSK
Shionogi
Salix
Takeda Pharmaceutical
Takeda Pharmaceuticals
Bayer
Salix (Bausch Health)
List of Tables
    Table 1. Global Opioid-Induced Constipation Market Value Comparison by Type (2024-2030) & (US$ Million)
    Table 2. Global Opioid-Induced Constipation Market Value Comparison by Application (2024-2030) & (US$ Million)
    Table 3. Global Opioid-Induced Constipation Market Competitive Situation by Manufacturers in 2023
    Table 4. Global Opioid-Induced Constipation Sales (K Units) of Key Manufacturers (2019-2024)
    Table 5. Global Opioid-Induced Constipation Sales Market Share by Manufacturers (2019-2024)
    Table 6. Global Opioid-Induced Constipation Revenue (US$ Million) by Manufacturers (2019-2024)
    Table 7. Global Opioid-Induced Constipation Revenue Share by Manufacturers (2019-2024)
    Table 8. Global Market Opioid-Induced Constipation Average Price (USD/Unit) of Key Manufacturers (2019-2024)
    Table 9. Global Key Players of Opioid-Induced Constipation, Industry Ranking, 2022 VS 2023 VS 2024
    Table 10. Global Key Manufacturers of Opioid-Induced Constipation, Manufacturing Sites & Headquarters
    Table 11. Global Key Manufacturers of Opioid-Induced Constipation, Product Type & Application
    Table 12. Global Key Manufacturers of Opioid-Induced Constipation, Date of Enter into This Industry
    Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 14. Global Opioid-Induced Constipation by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Opioid-Induced Constipation as of 2023)
    Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
    Table 16. Global Opioid-Induced Constipation Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 17. Global Opioid-Induced Constipation Sales by Region (2019-2024) & (K Units)
    Table 18. Global Opioid-Induced Constipation Sales Market Share by Region (2019-2024)
    Table 19. Global Opioid-Induced Constipation Sales by Region (2025-2030) & (K Units)
    Table 20. Global Opioid-Induced Constipation Sales Market Share by Region (2025-2030)
    Table 21. Global Opioid-Induced Constipation Revenue by Region (2019-2024) & (US$ Million)
    Table 22. Global Opioid-Induced Constipation Revenue Market Share by Region (2019-2024)
    Table 23. Global Opioid-Induced Constipation Revenue by Region (2025-2030) & (US$ Million)
    Table 24. Global Opioid-Induced Constipation Revenue Market Share by Region (2025-2030)
    Table 25. North America Opioid-Induced Constipation Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 26. North America Opioid-Induced Constipation Sales by Country (2019-2024) & (K Units)
    Table 27. North America Opioid-Induced Constipation Sales by Country (2025-2030) & (K Units)
    Table 28. North America Opioid-Induced Constipation Revenue by Country (2019-2024) & (US$ Million)
    Table 29. North America Opioid-Induced Constipation Revenue by Country (2025-2030) & (US$ Million)
    Table 30. Europe Opioid-Induced Constipation Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 31. Europe Opioid-Induced Constipation Sales by Country (2019-2024) & (K Units)
    Table 32. Europe Opioid-Induced Constipation Sales by Country (2025-2030) & (K Units)
    Table 33. Europe Opioid-Induced Constipation Revenue by Country (2019-2024) & (US$ Million)
    Table 34. Europe Opioid-Induced Constipation Revenue by Country (2025-2030) & (US$ Million)
    Table 35. Asia Pacific Opioid-Induced Constipation Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 36. Asia Pacific Opioid-Induced Constipation Sales by Region (2019-2024) & (K Units)
    Table 37. Asia Pacific Opioid-Induced Constipation Sales by Region (2025-2030) & (K Units)
    Table 38. Asia Pacific Opioid-Induced Constipation Revenue by Region (2019-2024) & (US$ Million)
    Table 39. Asia Pacific Opioid-Induced Constipation Revenue by Region (2025-2030) & (US$ Million)
    Table 40. Latin America Opioid-Induced Constipation Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 41. Latin America Opioid-Induced Constipation Sales by Country (2019-2024) & (K Units)
    Table 42. Latin America Opioid-Induced Constipation Sales by Country (2025-2030) & (K Units)
    Table 43. Latin America Opioid-Induced Constipation Revenue by Country (2019-2024) & (US$ Million)
    Table 44. Latin America Opioid-Induced Constipation Revenue by Country (2025-2030) & (US$ Million)
    Table 45. Middle East & Africa Opioid-Induced Constipation Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 46. Middle East & Africa Opioid-Induced Constipation Sales by Country (2019-2024) & (K Units)
    Table 47. Middle East & Africa Opioid-Induced Constipation Sales by Country (2025-2030) & (K Units)
    Table 48. Middle East & Africa Opioid-Induced Constipation Revenue by Country (2019-2024) & (US$ Million)
    Table 49. Middle East & Africa Opioid-Induced Constipation Revenue by Country (2025-2030) & (US$ Million)
    Table 50. Global Opioid-Induced Constipation Sales (K Units) by Type (2019-2024)
    Table 51. Global Opioid-Induced Constipation Sales (K Units) by Type (2025-2030)
    Table 52. Global Opioid-Induced Constipation Sales Market Share by Type (2019-2024)
    Table 53. Global Opioid-Induced Constipation Sales Market Share by Type (2025-2030)
    Table 54. Global Opioid-Induced Constipation Revenue (US$ Million) by Type (2019-2024)
    Table 55. Global Opioid-Induced Constipation Revenue (US$ Million) by Type (2025-2030)
    Table 56. Global Opioid-Induced Constipation Revenue Market Share by Type (2019-2024)
    Table 57. Global Opioid-Induced Constipation Revenue Market Share by Type (2025-2030)
    Table 58. Global Opioid-Induced Constipation Price (USD/Unit) by Type (2019-2024)
    Table 59. Global Opioid-Induced Constipation Price (USD/Unit) by Type (2025-2030)
    Table 60. Global Opioid-Induced Constipation Sales (K Units) by Application (2019-2024)
    Table 61. Global Opioid-Induced Constipation Sales (K Units) by Application (2025-2030)
    Table 62. Global Opioid-Induced Constipation Sales Market Share by Application (2019-2024)
    Table 63. Global Opioid-Induced Constipation Sales Market Share by Application (2025-2030)
    Table 64. Global Opioid-Induced Constipation Revenue (US$ Million) by Application (2019-2024)
    Table 65. Global Opioid-Induced Constipation Revenue (US$ Million) by Application (2025-2030)
    Table 66. Global Opioid-Induced Constipation Revenue Market Share by Application (2019-2024)
    Table 67. Global Opioid-Induced Constipation Revenue Market Share by Application (2025-2030)
    Table 68. Global Opioid-Induced Constipation Price (USD/Unit) by Application (2019-2024)
    Table 69. Global Opioid-Induced Constipation Price (USD/Unit) by Application (2025-2030)
    Table 70. Takeda Pharmaceuticals Corporation Information
    Table 71. Takeda Pharmaceuticals Description and Business Overview
    Table 72. Takeda Pharmaceuticals Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 73. Takeda Pharmaceuticals Opioid-Induced Constipation Product
    Table 74. Takeda Pharmaceuticals Recent Developments/Updates
    Table 75. Bayer Corporation Information
    Table 76. Bayer Description and Business Overview
    Table 77. Bayer Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 78. Bayer Opioid-Induced Constipation Product
    Table 79. Bayer Recent Developments/Updates
    Table 80. Sanofi Corporation Information
    Table 81. Sanofi Description and Business Overview
    Table 82. Sanofi Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 83. Sanofi Opioid-Induced Constipation Product
    Table 84. Sanofi Recent Developments/Updates
    Table 85. Mallinckrodt Corporation Information
    Table 86. Mallinckrodt Description and Business Overview
    Table 87. Mallinckrodt Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 88. Mallinckrodt Opioid-Induced Constipation Product
    Table 89. Mallinckrodt Recent Developments/Updates
    Table 90. Salix (Bausch Health) Corporation Information
    Table 91. Salix (Bausch Health) Description and Business Overview
    Table 92. Salix (Bausch Health) Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 93. Salix (Bausch Health) Opioid-Induced Constipation Product
    Table 94. Salix (Bausch Health) Recent Developments/Updates
    Table 95. AstraZeneca Corporation Information
    Table 96. AstraZeneca Description and Business Overview
    Table 97. AstraZeneca Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 98. AstraZeneca Opioid-Induced Constipation Product
    Table 99. AstraZeneca Recent Developments/Updates
    Table 100. Progenics Pharmaceuticals Corporation Information
    Table 101. Progenics Pharmaceuticals Description and Business Overview
    Table 102. Progenics Pharmaceuticals Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 103. Progenics Pharmaceuticals Opioid-Induced Constipation Product
    Table 104. Progenics Pharmaceuticals Recent Developments/Updates
    Table 105. Purdue Pharm Corporation Information
    Table 106. Purdue Pharm Description and Business Overview
    Table 107. Purdue Pharm Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 108. Purdue Pharm Opioid-Induced Constipation Product
    Table 109. Purdue Pharm Recent Developments/Updates
    Table 110. Nektar Therapeutics Corporation Information
    Table 111. Nektar Therapeutics Description and Business Overview
    Table 112. Nektar Therapeutics Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 113. Nektar Therapeutics Opioid-Induced Constipation Product
    Table 114. Nektar Therapeutics Recent Developments/Updates
    Table 115. Daiichi Sankyo Corporation Information
    Table 116. Daiichi Sankyo Description and Business Overview
    Table 117. Daiichi Sankyo Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 118. Daiichi Sankyo Opioid-Induced Constipation Product
    Table 119. Daiichi Sankyo Recent Developments/Updates
    Table 120. Prestige Corporation Information
    Table 121. Prestige Description and Business Overview
    Table 122. Prestige Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 123. Prestige Opioid-Induced Constipation Product
    Table 124. Prestige Recent Developments/Updates
    Table 125. GSK Corporation Information
    Table 126. GSK Description and Business Overview
    Table 127. GSK Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 128. GSK Opioid-Induced Constipation Product
    Table 129. GSK Recent Developments/Updates
    Table 130. Shionogi Corporation Information
    Table 131. Shionogi Description and Business Overview
    Table 132. Shionogi Opioid-Induced Constipation Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 133. Shionogi Opioid-Induced Constipation Product
    Table 134. Shionogi Recent Developments/Updates
    Table 135. Key Raw Materials Lists
    Table 136. Raw Materials Key Suppliers Lists
    Table 137. Opioid-Induced Constipation Distributors List
    Table 138. Opioid-Induced Constipation Customers List
    Table 139. Opioid-Induced Constipation Market Trends
    Table 140. Opioid-Induced Constipation Market Drivers
    Table 141. Opioid-Induced Constipation Market Challenges
    Table 142. Opioid-Induced Constipation Market Restraints
    Table 143. Research Programs/Design for This Report
    Table 144. Key Data Information from Secondary Sources
    Table 145. Key Data Information from Primary Sources
List of Figures
    Figure 1. Product Picture of Opioid-Induced Constipation
    Figure 2. Global Opioid-Induced Constipation Market Value Comparison by Type (2024-2030) & (US$ Million)
    Figure 3. Global Opioid-Induced Constipation Market Share by Type in 2023 & 2030
    Figure 4. Methylnaltrexone Bromide Product Picture
    Figure 5. Lubiprostone Product Picture
    Figure 6. Naloxegol Product Picture
    Figure 7. Others Product Picture
    Figure 8. Global Opioid-Induced Constipation Market Value Comparison by Application (2024-2030) & (US$ Million)
    Figure 9. Global Opioid-Induced Constipation Market Share by Application in 2023 & 2030
    Figure 10. Hospital
    Figure 11. Pharmacy
    Figure 12. Other
    Figure 13. Global Opioid-Induced Constipation Revenue, (US$ Million), 2019 VS 2023 VS 2030
    Figure 14. Global Opioid-Induced Constipation Market Size (2019-2030) & (US$ Million)
    Figure 15. Global Opioid-Induced Constipation Sales (2019-2030) & (K Units)
    Figure 16. Global Opioid-Induced Constipation Average Price (USD/Unit) & (2019-2030)
    Figure 17. Opioid-Induced Constipation Report Years Considered
    Figure 18. Opioid-Induced Constipation Sales Share by Manufacturers in 2023
    Figure 19. Global Opioid-Induced Constipation Revenue Share by Manufacturers in 2023
    Figure 20. The Global 5 and 10 Largest Opioid-Induced Constipation Players: Market Share by Revenue in 2023
    Figure 21. Opioid-Induced Constipation Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
    Figure 22. Global Opioid-Induced Constipation Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
    Figure 23. North America Opioid-Induced Constipation Sales Market Share by Country (2019-2030)
    Figure 24. North America Opioid-Induced Constipation Revenue Market Share by Country (2019-2030)
    Figure 25. U.S. Opioid-Induced Constipation Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 26. Canada Opioid-Induced Constipation Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 27. Europe Opioid-Induced Constipation Sales Market Share by Country (2019-2030)
    Figure 28. Europe Opioid-Induced Constipation Revenue Market Share by Country (2019-2030)
    Figure 29. Germany Opioid-Induced Constipation Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 30. France Opioid-Induced Constipation Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 31. U.K. Opioid-Induced Constipation Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 32. Italy Opioid-Induced Constipation Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 33. Russia Opioid-Induced Constipation Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 34. Asia Pacific Opioid-Induced Constipation Sales Market Share by Region (2019-2030)
    Figure 35. Asia Pacific Opioid-Induced Constipation Revenue Market Share by Region (2019-2030)
    Figure 36. China Opioid-Induced Constipation Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 37. Japan Opioid-Induced Constipation Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 38. South Korea Opioid-Induced Constipation Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 39. India Opioid-Induced Constipation Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 40. Australia Opioid-Induced Constipation Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 41. Taiwan Opioid-Induced Constipation Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 42. Indonesia Opioid-Induced Constipation Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 43. Thailand Opioid-Induced Constipation Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 44. Malaysia Opioid-Induced Constipation Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 45. Philippines Opioid-Induced Constipation Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 46. Latin America Opioid-Induced Constipation Sales Market Share by Country (2019-2030)
    Figure 47. Latin America Opioid-Induced Constipation Revenue Market Share by Country (2019-2030)
    Figure 48. Mexico Opioid-Induced Constipation Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 49. Brazil Opioid-Induced Constipation Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 50. Argentina Opioid-Induced Constipation Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 51. Middle East & Africa Opioid-Induced Constipation Sales Market Share by Country (2019-2030)
    Figure 52. Middle East & Africa Opioid-Induced Constipation Revenue Market Share by Country (2019-2030)
    Figure 53. Turkey Opioid-Induced Constipation Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 54. Saudi Arabia Opioid-Induced Constipation Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 55. U.A.E Opioid-Induced Constipation Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 56. Global Sales Market Share of Opioid-Induced Constipation by Type (2019-2030)
    Figure 57. Global Revenue Market Share of Opioid-Induced Constipation by Type (2019-2030)
    Figure 58. Global Opioid-Induced Constipation Price (USD/Unit) by Type (2019-2030)
    Figure 59. Global Sales Market Share of Opioid-Induced Constipation by Application (2019-2030)
    Figure 60. Global Revenue Market Share of Opioid-Induced Constipation by Application (2019-2030)
    Figure 61. Global Opioid-Induced Constipation Price (USD/Unit) by Application (2019-2030)
    Figure 62. Opioid-Induced Constipation Value Chain
    Figure 63. Opioid-Induced Constipation Production Process
    Figure 64. Channels of Distribution (Direct Vs Distribution)
    Figure 65. Distributors Profiles
    Figure 66. Bottom-up and Top-down Approaches for This Report
    Figure 67. Data Triangulation
    Figure 68. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Leap India

SIMILAR REPORTS

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions